Topas Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Topas Therapeutics's estimated annual revenue is currently $3.7M per year.
- Topas Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Topas Therapeutics has 24 Employees.
- Topas Therapeutics grew their employee count by -11% last year.
Topas Therapeutics's People
| Name | Title | Email/Phone |
|---|
Topas Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Topas Therapeutics?
Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver's natural immunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering. Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction, and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies. Topas' investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
keywords:N/A
N/A
Total Funding
24
Number of Employees
$3.7M
Revenue (est)
-11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Topas Therapeutics News
... and participated in several financing rounds and successful spin-offs, such as Topas Therapeutics, Celmatix and CureXsys.
Other Companies in Hamburg
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.4M | 24 | 4% | N/A |
#2 | $6M | 24 | 14% | N/A |
#3 | $2.4M | 24 | -23% | N/A |
#4 | N/A | 24 | 14% | N/A |
#5 | $2.5M | 25 | -22% | N/A |